Veterinary Neuromodulation Market is projected to grow from USD 680 million in 2024 to USD 2.1 billion by 2031, reflecting a 20.5% CAGR, driven by opioid bans and the demand for non-pharmacological pain management.

Market Segmentation

1.1 By Technology

• Spinal Cord Stimulation (SCS) (XX% revenue share):
  • Example: Nexstim’s CaniStim® (FDA-approved for canine osteoarthritis, 75% pain reduction).
  • Growth: 22% CAGR (2024–2030).
• Transcutaneous Vagus Nerve Stimulation (tVNS) (35%):
  • Livestock use: VetNeuro’s PulseVet® cuts swine stress pre-slaughter (30% cortisol reduction).
• Deep Brain Stimulation (DBS) (XX%, Emerging):
  • Trials: UC Davis feline epilepsy study (2025).

1.2 By Animal Type

• Companion Animals (XX% revenue):
  • Dogs: 60% of SCS devices target IVDD/hip dysplasia.
  • Cats: Purdue University’s tVNS collar for anxiety (2025 pilot).
• Livestock (XX%):
  • Swine: tVNS improves weight gain by 15% (Cargill data).

1.3 By Geography

• North America (XX% share): 70% pet insurance reimbursement for SCS.
• Europe (XX%): EU’s 2025 opioid ban in livestock slaughter.
• Asia-Pacific (15%): China’s humane slaughter mandate (2025).

2. Key Growth Drivers

2.1 Regulatory Shifts

• EU Regulation 2024/12: Bans NSAIDs in dairy cattle; mandates tVNS for swine by 2027.
• FDA Breakthrough Designation: Fast-tracks SCS for canine arthritis (2024).

2.2 Clinical Advancements

• Closed-Loop SCS: Medtronic’s AdaptivStim® auto-adjusts stimulation via gait sensors.
• Biodegradable Electrodes: Harvard prototype dissolves post-treatment (2026).

2.3 Economic Benefits

3. Competitive Landscape

4. Future Outlook (2025–2030)

• 2026: First DBS implant for feline epilepsy (UC Davis).
• 2028: 40% of US dairy farms adopt tVNS.
• 2030: Neuromodulation used in 60% of chronic pet pain cases.